{
    "symbol": "XAIR",
    "quarter": 2,
    "year": 2023,
    "date": "2022-11-09 02:38:05",
    "content": " And to include our highlights for the pipeline, I would like to remind everyone that we have now completed an adult pneumonia study, three bronchiolitis studies, two NTM studies, along with several other studies to give us in excess of 5000 NO administrations at 150 parts per million to 250 parts per million to over 170 patients with an excellent safety profile. For the fiscal quarter ended September 30, 2022, the company had a gap net loss of $12.8 million, of which $12 million or $0.40 per share was attributable to the shareholders of Beyond Air, Inc. compared with a net loss of $8.7 million or $0.36 per share for the fiscal quarter ended September 30, 2021. Net cash used by the company, or cash burn, including Beyond Cancer, was $10.4 million during the quarter ended September 30, 2022, which includes a $2.5 million payment to Circassia in accordance with our settlement agreement."
}